AbbVie Inc. $ABBV Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 17.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,025,985 shares of the company’s stock after buying an additional 607,653 shares during the quarter. AbbVie comprises approximately 1.6% of Federated Hermes Inc.’s portfolio, making the stock its 4th largest holding. Federated Hermes Inc.’s holdings in AbbVie were worth $932,177,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the second quarter valued at approximately $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the second quarter valued at approximately $36,000. Delos Wealth Advisors LLC bought a new stake in AbbVie in the 2nd quarter valued at $39,000. Finally, Bear Mountain Capital Inc. grew its position in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after buying an additional 173 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 1.4%

Shares of NYSE:ABBV opened at $223.92 on Wednesday. The business has a 50 day moving average of $225.14 and a 200-day moving average of $218.00. The stock has a market cap of $395.75 billion, a PE ratio of 169.64, a P/E/G ratio of 0.91 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 524.24%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Bank of America boosted their price objective on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Scotiabank initiated coverage on AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research report on Tuesday, November 4th. Finally, Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.84.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck billion‑dollar licensing deals with Novartis for oncology and Alzheimer’s programs, which expand near‑ and long‑term revenue optionality and signal external validation of AbbVie’s R&D. AbbVie and Novartis Announce Billion Dollar Licensing Deals for Oncology and Alzheimer’s Treatments
• Positive Sentiment: Berenberg raised its price target (to $275) and remains bullish on Skyrizi and Rinvoq momentum, a supportive analyst view that can boost investor sentiment. Berenberg Grows More Confident in AbbVie on Skyrizi and Rinvoq Momentum
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector delivering risankizumab, which could improve dosing convenience and broaden uptake for indications served by Skyrizi. This is a pipeline/utility win. AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion
• Positive Sentiment: Small institutional buying reported (Belpointe Asset Management increased its stake), a modest signal of shareholder confidence. Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
• Neutral Sentiment: Options and retail interest are elevated (coverage from Zacks on options flow and trending status); this can increase volatility but isn’t a fundamental catalyst by itself. Is the Options Market Predicting a Spike in AbbVie Stock?
• Neutral Sentiment: Corporate social impact news (AbbVie Foundation accelerator) and dividend‑king listings support the long‑term income story but are not immediate earnings drivers. The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program named several AbbVie drugs for its next negotiation cycle, including Part B products — a direct pricing risk that could pressure future revenues if negotiated prices are reduced. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: A competitor (Corcept) reported robust Phase III efficacy for an ovarian cancer drug, which could threaten market share in oncology areas where AbbVie competes. Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
• Negative Sentiment: Citigroup trimmed its price target to $230 and assigned a neutral rating, a modest analyst headwind that may cap upside near‑term. Citigroup Lowers Price Target on AbbVie

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.